GRIN2A and Alzheimer disease: In a recent experiment, NMDAR2A was identified as a CNS-specific EV surface marker, and it was shown in a multicenter study, including both discovery and validation cohorts, that the number of plasma EVs with NMDAR2A and L1CAM expression is lower in patients with AD in comparison to the healthy controls (129).